← Back to Search

Pulsed Field Ablation System

FARAPULSE Ablation for Atrial Fibrillation (ADVANTAGE AF Trial)

N/A
Waitlist Available
Led By Vivek Reddy
Research Sponsored by Boston Scientific Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects have symptomatic, documented, drug-resistant, Persistent AF, defined as: a. Documented: at a minimum a physician's note confirming the arrhythmia symptoms and durations AND, within 180 days of Enrollment Date, either: i. A 24-hour continuous ECG recording confirming continuous AF OR ii. Two ECGs from any regulatory cleared rhythm monitoring device showing continuous AF taken at least 7 days apart b. Drug-resistant: effectiveness failure of, intolerance to, or specific contraindication to at least one (1) AAD (Class I or III). c. Persistent: continuous AF for > 7 days and ≤ 365 days
Age ≥ 18 years of age, or older if specified by local law
Must not have
Contraindication to ICM insertion: Patients who cannot tolerate a subcutaneous, chronically-inserted LUX-Dx device
Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 360 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a device that uses electrical pulses to treat patients with persistent atrial fibrillation who do not respond to drugs. The device works by creating small scars in the heart to block abnormal electrical signals and restore normal rhythm.

Who is the study for?
This trial is for adults with symptomatic, drug-resistant persistent atrial fibrillation (AF) that's been continuous for more than 7 days but less than a year. Participants must have tried at least one antiarrhythmic drug without success and be able to attend all study-related tests. Exclusions include secondary AF due to reversible causes, severe heart conditions, certain pre-existing medical devices or implants, recent stroke or bleeding events, pregnancy, uncontrolled health issues like diabetes or sleep apnea, and those currently in other conflicting studies.
What is being tested?
The ADVANTAGE AF Study is testing the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System as a treatment option for people with persistent AF who haven't responded well to drugs. It's an open-label study where all participants receive the same intervention using this new ablation system designed specifically for their condition.
What are the potential side effects?
While specific side effects are not listed here, typical risks associated with ablation procedures may include discomfort at the site of catheter insertion, bleeding or bruising there too; rare chances of serious complications such as damage to blood vessels or heart tissue; potential arrhythmias during recovery; and very rarely stroke.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have persistent AF that's resistant to at least one heart rhythm medication.
Select...
I am at least 18 years old or meet the age requirement by local law.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot have a device implanted under my skin for health reasons.
Select...
I have severe lung disease or need extra oxygen.
Select...
I have had a stroke, TIA, or brain bleeding.
Select...
I have a tumor in my heart's left atrium.
Select...
I have had a blood clot that was not in my brain.
Select...
I am currently fighting an infection in my body.
Select...
- You currently have active COVID-19 or have recently had COVID-19 that hasn't fully cleared up. - Your diabetes is not well controlled, or your HgbA1c test result is higher than 8.0% in the last 3 months. - You have severe untreated obstructive sleep apnea, with more than 30 pauses in breathing per hour.
Select...
My kidney function is low, with an eGFR below 30, or I have had dialysis or a kidney transplant.
Select...
I have or had paralysis or weakness of one side of my diaphragm.
Select...
I have had heart surgery.
Select...
I do not have severe stomach or esophagus problems.
Select...
I have a known G6PD deficiency.
Select...
I have had issues with my blood vessels, but not with the common or middle ones.
Select...
I have not had cancer, except for skin cancer, in the last 2 years.
Select...
You have heart valve disease, hypertrophic cardiomyopathy, or certain heart conditions that could cause problems during the study.
Select...
I have had or am being evaluated for an organ or bone marrow transplant.
Select...
I have severe heart failure.
Select...
I am not pregnant, breastfeeding, and I use birth control.
Select...
I have a heart condition from birth with lasting effects.
Select...
I have a blood condition affecting clotting or platelet levels.
Select...
I have had bleeding in my stomach or intestines.
Select...
I have had a procedure to open my carotid artery.
Select...
My heart's left atrium is enlarged.
Select...
I have never had sustained ventricular tachycardia or ventricular fibrillation.
Select...
I have been hospitalized for heart failure.
Select...
I have inflammation or fluid around my heart.
Select...
I cannot or do not want to use blood thinners.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~360 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 360 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Phase 1: Rate of Persistent AF Acute Procedural Success
Phase 1: Rate of Persistent AF Chronic Success
Phase 1: Rate of Safety Events at 12 Months Post Procedure
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Pulsed Field Ablation (Phase 2)Experimental Treatment1 Intervention
PHASE 2 only
Group II: Pulsed Field Ablation (Phase 1)Experimental Treatment1 Intervention
PHASE 1 only

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Atrial Fibrillation (AF) include antiarrhythmic drugs, rate control drugs, and catheter ablation. Antiarrhythmic drugs, such as amiodarone and sotalol, work by altering the electrical signals in the heart to maintain a normal rhythm. Rate control drugs, like beta-blockers and calcium channel blockers, slow the heart rate by affecting the atrioventricular node. Catheter ablation, including the Pulsed Field Ablation (PFA) studied in the FARAPULSE system, targets and destroys small areas of heart tissue that cause irregular electrical signals, thereby restoring normal rhythm. PFA specifically uses electrical pulses to create precise lesions without damaging surrounding tissues, which is crucial for reducing complications and improving outcomes for AF patients.

Find a Location

Who is running the clinical trial?

Boston Scientific CorporationLead Sponsor
738 Previous Clinical Trials
855,711 Total Patients Enrolled
75 Trials studying Atrial Fibrillation
32,488 Patients Enrolled for Atrial Fibrillation
Vivek ReddyPrincipal InvestigatorMOUNT SINAI HOSPITAL
1 Previous Clinical Trials
583 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
583 Patients Enrolled for Atrial Fibrillation

Media Library

FARAPULSE Ablation System (Pulsed Field Ablation System) Clinical Trial Eligibility Overview. Trial Name: NCT05443594 — N/A
Atrial Fibrillation Research Study Groups: Pulsed Field Ablation (Phase 1), Pulsed Field Ablation (Phase 2)
Atrial Fibrillation Clinical Trial 2023: FARAPULSE Ablation System Highlights & Side Effects. Trial Name: NCT05443594 — N/A
FARAPULSE Ablation System (Pulsed Field Ablation System) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05443594 — N/A
~111 spots leftby Mar 2025